Health Canada brings updated Cosmetic Regulations into force under the Food and Drugs Act, mandating disclosure of 24 specific fragrance allergens on retail packaging to protect consumer health.

OTTAWA, ON — Health Canada announced that comprehensive amendments to the Cosmetic Regulations under the Food and Drugs Act have officially taken legal effect across Canada, mandating transparent ingredient labeling for fragrance allergens.
The updated federal rules end the legacy practice of listing proprietary chemical compounds under generic 'fragrance' or 'parfum' umbrella labels, requiring cosmetic manufacturers to explicitly disclose the presence of 24 recognized contact allergens—including limonene, linalool, and oakmoss extract—when concentrations exceed 0.001% in leave-on skin products or 0.01% in rinse-off soaps and shampoos. The regulations also authorize Health Canada to request ingredient safety dossiers directly from international distributors.
Health Canada officials affirmed that transparent packaging empowering consumers to identify contact allergens is essential to prevent severe dermatological reactions.
The Canadian Dermatology Association (CDA) strongly commended the updated labeling standards, highlighting that fragrance allergy is among the leading causes of contact dermatitis.
Cosmetics Alliance Canada collaborated with federal regulators to formulate transitional digital packaging label extensions.
Cosmetic manufacturers have an 18-month phase-in period to transition commercial retail shelf packaging to the new allergen labeling standards.
Governor Brian Kemp announces $85 million in state emergency stabilization grants to upgrade diagnostic equipment and retain emergency room physicians across 28 rural Georgia hospitals.

Nova Scotia Health expands mobile clinical outreach, deploying 12 custom primary care vans providing doctor appointments, immunizations, and prescription renewals across coastal towns.

New Jersey enacts statutory pharmaceutical oversight requiring drug manufacturers to justify price increases exceeding 15% and establishing penalty audits for pharmacy benefit managers.
